DENTSPLY SIRONA Inc. ( XRAY Quick Quote XRAY - Free Report) reported third-quarter 2022 adjusted earnings per share (EPS) of 41 cents, missing the Zacks Consensus Estimate of 59 cents by 30.5%. The bottom line declined 31.5% on a year-over-year basis.
On a GAAP basis, the company incurred a loss of $5.01, reflecting an improvement of 4.4% from the year-ago quarter. The company recorded a non-cash charge for the impairment of goodwill and intangible assets of $1.1 billion net of tax. The charge reflected the impact of macroeconomic factors as a result of weakened global demand, higher cost of capital, unfavorable foreign currency impacts, and increased raw material, supply chain and service costs.
Revenues in the quarter under review amounted to $947 million, missing the Zacks Consensus Estimate by 8.1%. The top line decreased 8.9% year over year. Sales were down 0.7% on an organic basis.
Management stated that it is encouraged by the double-digit growth in clear aligners, solid performance in Europe, and continued strong demand for Imaging equipment amid continued macroeconomic headwinds, including foreign currency impacts, global supply chain challenges, and regional softness in the United States and China. However, management was not satisfied with the results and stated that it has initiated a comprehensive review of the entire business to improve execution, build a winning portfolio and return to growth.
Business Details Consumables
Revenues of the Consumables segment fell 8.7% year over year and 2.5% on an organic basis in the third quarter to $391 million. Per management, the decline was led by softening demand in the United States and China, partially offset by the demand for preventive consumables.
Technologies & Equipment
Technologies & Equipment’s revenues were down 9% year over year to $556 million in the reported quarter. On an organic basis, net sales rose 0.6%. Higher demand for clear aligners and imaging equipment drove organic revenues, partially offset by lower CAD/CAM volumes.
Revenues by Geography
In the United States, revenues decreased 7.2% year over year to $357 million. Rest of World revenues fell 11.6% year over year to $232 million. European revenues declined 8.8% year over year to $358 million. However, sales were up 3% and 0.1% organically in the European and Rest of the World markets, respectively. Organic sales declined 5.2% in the U.S. market.
Gross profit in the reported quarter amounted to $508 million, down 10.7% on a year-over-year basis. The gross margin was 53.6%, contracting 110 basis points.
Selling, general and administrative expenses were $401 million, up 1.5% from the year-ago quarter. Research and development expenses amounted to $41 million, up 5.1% from the prior-year quarter.
Operating loss was $1.22 billion against an operating income of $132 million in the year-ago quarter.
DENTSPLY SIRONA exited the third quarter of 2022 with cash and cash equivalents of $418 million, up from $339 million at the end of December 2021.
Cumulative net cash provided by operating activities at the end of the third quarter was $375 million compared with $435 million in the year-ago period.
DENTSPLY SIRONA lowered its guidance for revenues and EPS in 2022 to reflect the adverse impact of macroeconomic headwinds. The company now projects 2022 revenues within $3.85-$3.88 billion, down from $4.1-$4.2 billion. The Zacks Consensus Estimate for the same is pegged at $4.05 billion. The outlook includes an organic sales decline of approximately 2%.
The company expects an adjusted EPS of $1.90-$2.00, down from the previous guidance of $2.35-$2.55. The Zacks Consensus Estimate for the same stands at $2.35.
DENTSPLY SIRONA ended the third quarter on a weak note, wherein both earnings and revenues missed the consensus mark. The company saw continued strong demand for Imaging equipment during the quarter as well as in European businesses. However, the ongoing macro headwinds impacted third-quarter results adversely, which is likely to continue for the rest of 2022. Weakness in the U.S. markets is also discouraging.
Zacks Rank and Key Picks
Currently, DENTSPLY SIRONA has a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are
ShockWave Medical ( SWAV Quick Quote SWAV - Free Report) , AMN Healthcare Services ( AMN Quick Quote AMN - Free Report) and McKesson ( MCK Quick Quote MCK - Free Report) , all carrying a Zacks Rank of 2 (Buy). You can see . the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
The Zacks Consensus Estimate for ShockWave Medical’s earnings per share is stable at $2.57 for 2022 and rose from $3.42 to $3.56 for 2023 in the past 60 days. SWAV has gained 43.1% so far this year.
ShockWave Medical delivered an earnings surprise of 146.1%, on average, in the last four quarters.
Estimates for AMN Healthcare Services have improved from earnings of $11.26 to $11.43 for 2022 and $8.30 to $8.39 for 2023 in the past 60 days. AMN has declined 1.6% so far this year.
AMN Healthcare Services delivered an earnings surprise of 10.96%, on average, in the last four quarters.
McKesson’s earnings per share estimates have increased from $24.42 to $24.75 for fiscal 2023 and $26.04 to $26.40 for fiscal 2024 in the past 60 days. MCK has gained 55.2% so far this year.
McKesson delivered an earnings surprise of 4.79%, on average, in the last four quarters.